Intense Treatment Regimen With Intravitreal Aflibercept Injection
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of intense dosing for a limited period in
patients who demonstrate refractory disease on monthly IAI. Patients will be followed for 52
weeks